Medifast, Inc.
NYSE:MEDPersonal Products & Services
-$0.01 today
- Market cap
- $136.43M
- Beta
- 0.66
- P/E (TTM)
- -6.2
- EPS (TTM)
- -$1.82
Volume 0.09M
Average 0.21M
Returns on capital
Medifast, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-9.4%
avg 42.9%
ROIC
-6.5%
avg 38.8%
ROA
-7.3%
avg 24.8%
Analysis
ROIC is currently the strongest return metric at -6.5% versus its period average of 38.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
James Maloney | Chief Financial Officer | USD 727.97K | 58 | — | — |
Nicholas Johnson | CEO & President | USD 610.46K | 46 | — | — |
Matthew Daryman | Manager of Investor Relations | — | — | — | — |
Steven Zenker | Vice President of Investor Relations | — | — | — | — |
Claudia C. Greninger | Chief Human Resources Officer | — | 52 | — | — |
Jonathan Barrett MacKenzie | Vice President of Finance & Chief Accounting Officer | — | 54 | 10.01K | 0.09% |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Mar 25, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
14
$1.74M
Sells
2
$226,288.77
Net Transaction Value
+$1.52M
Net buying
Most Active
Kiai Parsa
11 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 4, 26Nov 4, 2026 | Kiai Parsa Indirect | Buy | $8.6K$8,609.86 |
| Oct 28, 26Oct 28, 2026 | Kiai Parsa Indirect | Buy | $1.9K$1,934.19 |
| Oct 28, 26Oct 28, 2026 | Kiai Parsa Indirect | Buy | $66.1K$66,092.94 |
| Sep 29, 26Sep 29, 2026 | Chard Daniel R Indirect | Sell | $112K$111,951.12 |
| Sep 28, 26Sep 28, 2026 | Chard Daniel R Indirect | Sell | $114.3K$114,337.65 |
| Aug 26, 26Aug 26, 2026 | Kiai Parsa Indirect | Buy | $14.4K$14,409.26 |
| Aug 26, 26Aug 26, 2026 | Kiai Parsa Indirect | Buy | $514.7K$514,747.82 |
| Aug 24, 26Aug 24, 2026 | Kiai Parsa Indirect | Buy | $50.5K$50,530.32 |
| Aug 24, 26Aug 24, 2026 | Kiai Parsa Indirect | Buy | $1.4K$1,415.95 |
| Aug 20, 26Aug 20, 2026 | Kiai Parsa Indirect | Buy | $487.1K$487,065.31 |
1–10 of 16
Summary
Insiders reported 14 buys worth $1.74M and 2 sells worth $226,288.77 over the last 12 months. That adds up to net buying of $1.52M. Kiai Parsa was the most active insider with 11 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -37.7% | -15.6% (2yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -37.7% over three years. Forward estimates point to Revenue at -15.6% (2yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Medifast, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about MED's management, answered from reported figures.
Who manages MED?
Medifast, Inc. (MED) lists 6 active executives. The top listed executive is James Maloney, Chief Financial Officer.
Are MED insiders buying or selling?
Recent insider activity shows net selling of $5.53M.
Continue the stock analysis
Jump to another research area for this company.